|
- Iain Chessell PhD. - 15 years in big Pharma and previously Head of Pain Research for GSK, where he has overseen drug discovery and development from target inception to Phase III.
- Mark Treherne PhD. - Over 25 years experience in drug discovery, and formerly at Pfizer in the UK. Mark has been involved in raising over £60 million for more than 10 early-stage life science companies.
- Prof David Spanswick PhD. - 22 years in academia and 8 years in leadership positions in biotech. Highly specialised neuroscience expertise with a track record of entrepreneurial success.
- Chas Bountra PhD. -
A senior executive from Pharma, with experience in running all stages of drug discovery and development. Proven expertise in neurological and GI diseases, and establishing strong and productive collaboration between academia and industry. Specialist knowledge of translational medicine, and derisking assets progressing into clinical development
.
- Suresh Chahwala PhD. - A highly experienced Pharmaceutical Industry (Pfizer and Trigen a biotech company) Senior executive with proven track record of innovation, managing professional teams, delivering candidates and progressing compound in development to proof of concept. Key strengths include worldwide experience across a variety of therapeutic areas including neurodegeneration, cardiovascular and cancer; management of collaborations; mergers and acquisitions, including integration of activities and portfolio prioritisation
- Alan Naylor PhD. - Medicinal chemist with over 30 years experience in Research and Development within GSK. As a senior executive he was engaged in strategic, matrix and line functions with significant international responsibilities. He has an extensive track record of delivery across a wide variety of therapeutic areas, including the co-inventorship of Serevent. Extensive academic interactions have resulted in him being appointed to two visiting chairs at UK universities.
- Ann Hayes PhD. - The Ann Hayes Consultancy Ltd., 22 years in big pharma as director of research, with
responsibility for long term discovery strategies and portfolio management.
Now an independent consultant with a proven track record of success in
foundation and development of biotech companies. Holds several board and
advisory positions and has an established leadership position as an independent
consultant.
- Rob Bryant PhD. - Brychem Business Consulting, a provider of comprehensive consulting services to the fine chemical and intermediates industry.
- Sunil Shah PhD. - Oxygen Healthcare Limited, a provider organic and medicinal chemistry expertise to meet your drug discovery requirements.
- David Parry-Smith PhD. - ChiBio Informatics, a provider of bioinformatic services, R&D services and consulting services to the biotechnology and pharmaceutical industries.
|
